Slowed gut motility is the trade-off for powerful appetite suppression and significant weight loss
7 Persulfides are superior radical scavengers
The concern is about early worsening during the first several months of rapid glucose improvement, not the long-term effects
The guidelines state, GLP-1 RAs may be considered for weight-loss in patients who have completed cancer therapy and may be considered with caution for patients on stable endocrine-based cancer therapies based on limited observational safety data. They also say, GLP-1 RAs cannot be recommended currently for patients receiving or initiating chemotherapies and/or immunotherapies due to lack of safety and outcomes data. Iyengar is director of Survivorship Services at Winship Cancer Institute of Emory University, a clinical member of Winships Glenn Family Breast Center, an associate professor and co-director of the Breast Medical Oncology Program in the Department of Hematology and Medical Oncology at Emory University School of Medicine, and co-editor-in-chief of the journal ONCOLOGY
Cost and accessibility: a frank look Cost is often the decisive factor
This can be seen as a problem due to lack of standardization or as a feature that actually makes the findings more robust: whatever design flaws exist in one study are probably absent from the rest
